regayip zehir

[EuroIntervention @EuroInterventio]

The ULTRACOLOR Trial finds that ultrasound-guided femoral access for complex PCI doesn't significantly reduce bleeding or vascular complications compared to fluoroscopy guidance. However, it supports the feasibility and safety of ultrasound guidance. https://t.co/zYZEDqQumn

[JACC Journals @JACCJournals]

In this prospective pilot study, Dr. @MarieF_Poulin, et al. examined the safety & feasibility of incorporating routine EP studies performed by #TAVR operators to assess atrioventricular conduction during TAVR procedures. https://t.co/g26R10z1nv #JACCINT #EPeeps

[EuroIntervention @EuroInterventio]

This study showed that in patients with severe AS and stable CAD scheduled for TAVI, performance of PCI after TAVI seems to be associated with improved 2-year clinical outcomes compared with other revascularisation timing strategies. #EAPCI https://t.co/aewSaxxUKQ

[C. Michael Gibson MD @CMichaelGibson]

Amyloid stabilizer, Acoramidis, cuts death and improves quality of life in patients with ATTR-amyloid cardiomyopathy. Dr. Gillmore and I review the results of the ATTRibute-CM trial presented at #ESCCongress

[Francesco Costa @Costa_F_8]

#FIRE trial shows physio guided complete revasc reduce hard endpoints in elderly. Another confirmation that complete revasc is key in ACS.
Congrats to all the investigators for this important trial 🇮🇹
@GianlucaCampo78 @Tebaldi_Matteo @SimoneBiscaglia

https://t.co/2T9uCIX7aI

[European Society of Cardiology @escardio]

In iron-deficient patients with #HeartFailure and reduced or mildly reduced left ventricular ejection fraction (#LVEF), intravenous ferric carboxymaltose (FCM) is associated with a reduced risk of the composite outcome of total CV hospitalisation and CV death through 52 weeks compared with placebo 👇

#ESCCongress
Effects of FCM on recurrent #HF hospitalisations

[C. Michael Gibson MD @CMichaelGibson]

ECLS-SHOCK randomized trial showed in patients with AMI and cardiogenic shock (n=877), VA-ECMO no different than control in reducing 30-day all-cause mortality, more bleeding and peripheral ischemic complications with VA-ECMO #ESCCongress

[EuroIntervention @EuroInterventio]

This new study suggests that TAVI can effectively reduce mitral regurgitation severity and symptoms in patients with atrial and ventricular functional mitral regurgitation, but the reduction is less pronounced in patients with primary mitral regurgitation. https://t.co/ot8RpgSy0u

[C. Michael Gibson MD @CMichaelGibson]

The new ESC guidelines give Aspirin mono therapy a Class 1 recommendation & thienopyridine therapy a class 2b recommendation for chronic CAD thx.

Based on the HOST Exam trial https://t.co/HXXn9uxIlb and the CAPRIE trial https://t.co/hGGrZppFLv what is your practice? #esccongress

[Timir Paul, MD, PhD, FACC, FSCAI, FAHA @timir_paul]

Read the July SCAI -TIP
✅Renal Artery Intervention: Current State of the Art | SCAI
✳️RAS still a treatment option
🔷Select appropriate patients
✅Confirm hemodynamically significant RAS
❇️R/o advanced nephropathy
❇️RAS will work ⁦@HadyLichaaMD⁩
https://t.co/yAL7WuwRVB

[Sergio Kaiser MD, PhD, FACC, FESC 🇧🇷🇮🇱🇷🇴🇺🇦 @pabeda1]

What is your current practice regarding beta-blocker use in CCS? Here is a comparison between 2014 and 2023 US guidelines and between ESC and US guidelines.
DOI: 10.1016/j.jacc.2023.06.006 #cardiology #CardioTwitter #CardioEd @drpablocorral @SABOURETCardio @SeguraCardio

[Javier Torres @JTLLERGO]

⚠️ Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension‼️

📍 Inhibits hepatic angiotensinogen synthesis

📍 Decreases ambulatory blood pressure were sustained for up to 24 weeks

@NEJM @secardiologia @clinica_sec @SEMERGENap

https://t.co/hZHt3U97Ye

[RTHahnMD @hahn_rt]

Fantastic discussion of LVOTmodification by the Master @AdamGreenbaumMD. He says: 1) MAC+SEVERE MR➡️any modification procedure followed by TMVR, 2) isolated MAC-MS➡️SESAME and follow for improvement in sx’s/gradient (some may not need TMVR)! #CSI2023 @sameergafoor

[Abdulla A. Damluji, MD, PhD @DrDamluji]

Association of Beta-Blocker Therapy With Cardiovascular Outcomes in Patients With Stable Ischemic Heart Disease: @JACCJournals

My friend @MichaelGNanna is studying the effects of beta blockers and calcium channel blockers in older pts with SIHD: @PCORI

15-point summary 👇👇👇

[C. Michael Gibson MD @CMichaelGibson]

Don’t take a job where you have all the responsibility for the outcome but little or no control over the process #cmgsays

[Athanasios Saratzis @a_saratzis]

The best way to prolong the life of people with severe peripheral arterial disease is not a fancy stent; it's medical care & proper risk-factor control (https://t.co/wwgBhC6VtW) 🧵

[Ali Tekin @alitekintr]

Tamamen ücretsiz bir şekilde Kitap/Makale gibi belgelerinizi istediğiniz dile çevirebileceğiniz harika siteler paylaşacağım.

[JACC Journals @JACCJournals]

Dr. @CMichaelGibson on the new formation of #aspirin at #TCT2022

#ACCIC #CardioEd #CardioTwitter #PCI #JACC

[José R. Juanatey @JoseJuanatey]

#esccongress2022 COURAGE don’t revascularize those patients ; ORBITA don’t revascularize those patients; ISCHEMIA don’t revascularize those patients; REVIVE don’t revascularize those patients! How relevant clinical implications!! @secardiologia @escardio @cardiologiaCHUS